 |
2 Diseases |  |
27 Trials |
|
27 Trials |  |
1089 News |  |
| «12...45678910111213141516» |
- vericiguat (BAY 1021189) / Bayer, Merck (MSD)
[VIRTUAL] The VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial () - May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_578;
- vericiguat (BAY 1021189) / Bayer, Merck (MSD)
[VIRTUAL] The VITALITY-HFpEF Trial (Evaluate the Efficacy and Safety of the Oral sGC Stimulator Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With Heart Failure and Preserved. () - May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_576;
- vericiguat (BAY 1021189) / Bayer, Merck (MSD)
[VIRTUAL] Effect of Vericiguat on Left Ventricular Function: The VICTORIA Echocardiographic Sub-Study. () - May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_575;
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Should we add to usual Treatment? @JavedButler1 @lamcardio @JustinEzekowitz Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction @gcfmd @ShelleyZieroth @ValleAlfonso @JoseJuanatey https://t.co/pB77qNme7B (Twitter) - May 18, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Vericiguat (Twitter) - May 17, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, Rovi Pharmaceuticals Laboratories
Is it possible to combine Vericiguat with Entresto? (Twitter) - May 3, 2020
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD)
VICTORIA: Vericiguat Seen as Novel Success in High-Risk HFrEF https://t.co/mhODkx3TP5 vía @medscape (Twitter) - May 3, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Good points: Vericiguat compared to placebo in HF pts who met inclusion criteria had Lower PEP of HF hosp or mortality Lower HF hospitalizations No difference in mortality Numerically higher syncope & anemia Will be interesting to see how o/c differ based on BNP levels (Twitter) - Apr 21, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Intriguing modes of actions of vericiguat, given it increases soluble guanylate cyclase in the absence of nitric oxide, it's role in pts with reduced EF will be interesting to learn from! (Twitter) - Apr 21, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Discussion on #vericiguat in #HF @novitskiynic @AnkurKalraMD @CousiratLiendro @EkateriniL @BoggildLab @MihaiTrofenciuc @jilliannec @kamalcardiodoc1 @DrFerNunez @rahatheart1 @boback @Uqayyum123 @DrJenniferCo_Vu @rbcasado @SilCastelletti @Pooh_Velagapudi @gina_lundberg @adityadoc1 (Twitter) - Apr 21, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #hfupdate20 Is Vericiguat another victory in HFrEF? Dr @JustinEzekowitz summarizes the #VICTORIA trial below: ⬇️ primary endpt: CVD/hosp for HF HR 0.90 (0.82-0.98) Mostly driven by hospitalization for HF, nonsignificant benefit for CVD in secondary endpt (Twitter) - Apr 18, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
#ACC20. Vericiguat reduce mortalitatea de cauză cardiovasculară cu 10% la pacienții cu insuficiență cardiacă cu fracție de ejecție scăzutăDr. Diana Chițimuș https://t.co/7iD2g6lUzj (Twitter) - Apr 10, 2020
- || rivaroxaban / Generic mfg., vericiguat (BAY 1021189) / Bayer, Merck (MSD)
#VisualAbstract de #ACC20 📍Victoria Trial: VERICIGUAT en IC 📍Voyager PAD: Rivaroxaban2.5+AAS en 👥 con PAD revascularizada y sintomática @secardiologia @Cardiology (Twitter) - Apr 1, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: End of poll. Most voters (63%) believe that Vericiguat may have a role in selected cases. (Twitter) - Mar 29, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Novel therapy for high risk HFrEF patients with #Vericiguat, a novel oral Guanylate Cyclase Inhibitor on background of optimal medical therapy as seen in VICTORIA trial. @JustinEzekowitz @coconnormd Congratulations! More good news for the HF world. (Twitter) - Mar 29, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Important data- definitely another “win” in #heartfailure - Vericiguat for advanced HFrEF after a worsening event; novel indication and needed therapy @gcfmd @texhern @ACCinTouch (Twitter) - Mar 29, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: ICYMI: Vericiguat, a novel oral soluble guanylate cyclase stimulator, reduced the incidence of HF hospitalization or CV death compared with placebo in patients with high-risk HF. @pwa_2000 @CVC_UAlberta @NMHheartdoc @ACCinTouch #ACC2020 https://t.co/6WuVxLdt5K (Twitter) - Mar 29, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Not bad to have another option for HFrEF pts but hard to imagine ever starting vericiguat before ARNI or SGLT2i (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: ICYMI: Vericiguat, a novel oral soluble guanylate cyclase stimulator, reduced the incidence of HF hospitalization or CV death compared with placebo in patients with high-risk HF. @pwa_2000 @CVC_UAlberta @NMHheartdoc @ACCinTouch #ACC20 https://t.co/6WuVxLdt5K (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: But i will say that the PCKS9 inhibitor with high price tags did an amazing job of ensuring we got all of our patients on statins! I’m hoping if there are appropriate guardrails in place before ordering vericiguat, we can do a better job of maximizing GDMT for those who need it! (Twitter) - Mar 28, 2020
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Vericiguat llegó tarde a la fiesta (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #VICTORIA trial full paper in @NEJM 👉🏻👉🏻 https://t.co/2VPaeWygiu Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction @ACCinTouch @ESC_Journals @nossikoff @ALEX_MISCHIE @lamcardio @HFA_President @ShelleyZieroth @DrRyanPDaly @HFSA @hvanspall @mmamas1973 @Hragy (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Just published in @NEJM. VICTORIA study, led by PI @IHVInews @coconnormd, demonstrates that vericiguat decreases the composite endpoint of CV deaths and #heartfailure hospitalizations in patients with HFrEF. @DoctorRTC @mpsotka @ShashankSinhaMD @InovaHealth (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, Rovi Pharmaceuticals Laboratories
Clinical: My first take on these results is that I would start an LCZ696 before starting vericiguat in HFrEF (only 16% of the patients were on ARNI), as the results of PARADIGM-HF are more impressive than what we see here. But keen to hear others thoughts esp. @coconnormd @texhern 4/4 (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #ACC20 LBCT—VICTORIA trial shows that vericiguat was associated with a significant reduction in the composite endpoint of CV deaths and #heartfailure hospitalizations in HF patients with reduced EF. @coconnormd @ShashankSinhaMD @mpsotka (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: .@lamcardio discusses the results of the VICTORIA trial and the potential to reduce CV death & rehospitalization in patients with severe chronic heart failure and reduced ejection fraction with #Vericiguat: https://t.co/nm6mys5A0X (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Ok, add #vericiguat to the list. @NMHheartdoc said it well: we now have the wonderful problem of polypharmacy in #HFrEF. Adds to the critical need to personalize treatment. Measure NO activity? Vasoreactivity? Clinical subgroups? Lots of work to do to get best therapy to our pts (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Adverse events, Late-breaking abstract: @ACCinTouch Late Breaking clinical trial, #VICTORIA RCT: for #HFrEF pts, PO daily vericiguat, a GC stimulator⬇️HF hospitalization/CV death & HF hospitalization (1st or recurrent). Adverse events: anemia/hypotension. URMs underrepresented. Study out in @NEJM @NMHheartdoc (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: vericiguat v. placebo improves Death/Hospitalization for HF in pts with Heart Failure- Nitric oxide and cGMP mechanism @NMHheartdoc gives his comments live... Watch live, right on comments in the context of what is available already to treat chronic HF @ACCinTouch (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Vericiguat reduces mortality, HF hospitalization in recently decompensated HFrEF -- VICTORIA trial shows "important opportunity to modulate further the natural history of HFrEF" @NMHheartdoc @dranulala @JJheart_doc @medpagecardio @ACCintouch #ACC2020 https://t.co/HEWN2lSUPg (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Breaking @ACCinTouch news: In #VICTORIA RCT Vericiguat reduced the Primary EP of HHF + CV death. However, the benefit was significant only for HHF but not for CV death @MarcoMetra @MicheleSenni @HFA_President @ShelleyZieroth @hvanspall @JJheart_doc @DBelardoMD @radcliffeCARDIO (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD), furosemide / Generic mfg.
Law of diminishing returns. Betablocker + Ace/Arb + MRA + SGLT2i + Sacubitril + Vericiguat +/- furosemide. Come one. (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), digoxin / Generic mfg., Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
Clinical: #ACC20 #acc20Virtual #WCCardio - Overall, the VICTORIA trial results are similar to agents shown to reduce hospitalization for systolic heart failure, but not alter all-cause mortality. Digoxin and ivabradine are in this group. Vericiguat may be better tolerated, however. (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
So where does vericiguat fit in? (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Vericiguat, a novel oral soluble guanylate cyclase stimulator, reduced the incidence of HF hospitalization or CV death compared with placebo in patients with high-risk HF. @pwa_2000 @CVC_UAlberta @NMHheartdoc @ACCinTouch #ACC2020 https://t.co/6WuVxKVSec (Twitter) - Mar 28, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #Vericiguat reduces composite of CV death & hospitalization but not CV mortality in #HFrEF (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Among patients with high-risk heart failure with reduced ejection fraction the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. https://t.co/W1oX1pQxAb (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Ravn5fKL3z (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
👆🏽#ACC20 #Vericiguat #VICTORIA #HFrEF @DrMarthaGulati @mmamas1973 @HeartOTXHeartMD @KTamirisaMD @ShelleyZieroth @AnkurKalraMD @paomorejon @CousiratLiendro @AndreasGevaert @GiuseppeGalati_ @BoggildLab @onco_cardiology @fischman_david @DrRajivsankar @DocSavageTJU @IAmDrIbrahim (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/1G6C4mVJW4 (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: VICTORIA: With Vericiguat, Less CV Death, Heart Failure Hospitalization Among High-Risk Patients https://t.co/r8nMNOOKHa via @AJMC_Journal (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: VICTORIA TRIAL: Vericiguat more effective than placebo 👉🏻 CV death or hospitalization 👍 Heart failure hospitalization 🤷♀️ no significant change in all cause mortality,higher risk #heartfailure population, sicker that paradigm and DAPA HF trial #ACC20 @JustinEzekowitz @texhern (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
vericiguat has modest benefit on composite HF hosp & CV death in HFrEF HR = 0.9, p=.019, CV death p-val=.269 #acc20 (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: -population had high baseline event rate -vericiguat reasonably tolerated #VICTORIA #ACC20 (Twitter) - Mar 28, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/umwPqPbOmb (Twitter) - Mar 28, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
#Vericiguat objetivo primario alcanzado #ACC20 @secardiologia @rafavidalperez (Twitter) - Mar 28, 2020
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal: Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. (Pubmed Central) - Mar 28, 2020
P2b
Vericiguat treatment for 12 weeks was associated with reductions in hsCRP and SUA, and a higher likelihood of achieving an hsCRP value of ≤3.0 mg/L and SUA value of <7.0 mg/dL.
- ||||| rivaroxaban / Generic mfg., vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Late-breaking abstract: #cardiotwitter #ACC20 #WCCardio virtual late-breaking clinical trials sessions starting in 1 hour at https://t.co/sQyzSfFUWm @ACCinTouch; for #heartfailure #VICTORIA trial of vericiguat; for #PAD #VOYAGER trial of rivaroxaban. @coconnormd (Twitter) - Mar 28, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Late Bresking Clinical Trial VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) Principal Investigator @IHVInews President @coconnormd Access live Saturday, March 28 9:00 AM CT on Hot Topics channel ACC.20/WCC Virtual (Twitter) - Mar 27, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Late-breaking abstract: Tune in tomorrow for the presentation of VICTORIA (Vericiguat Global Study In Subjects With HFrEF) at the virtual #ACC20 / #WCCardio Late Breaking Clinical Trials session. More information on how to access the session is available here: https://t.co/xfKRxlNn37 @JustinEzekowitz (Twitter) - Mar 27, 2020